Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
August 14, 2013; Copenhagen, Denmark;
Interim Report First Half 2013
• Reported positive top line results in Phase III study of ofatumumab in previously untreated chronic lymphocytic leukemia (CLL)
• Received Breakthrough Therapy Designation for daratumumab
• First half net sales of Arzerra® increased 40% over prior year
• Improved operating result by DKK 93 million over H1 2012
• Improved guidance and year-end cash balance
Help employers find you! Check out all the jobs and post your resume.